HEREDITARY PARAGANGLIOMA-PHEOCHROMOCYTOMA

Hereditary Paraganglioma-Pheochromocytoma — up to 40% of cases are hereditary, caused by variants in SDH subunit genes, where the specific gene mutated determines malignancy risk, multifocal disease likelihood, and surveillance protocol.

Whole genome sequencing evaluates SDHB, SDHC, SDHD, SDHAF2, and all other PGL/PCC-associated genes simultaneously — critical in a hereditary syndrome where the causative gene directly determines the clinical management pathway.

CLIA CertifiedCAP AccreditedISO 15189 Medical LabACMG ClassifiedHIPAA & GDPR100,000+ Genomes Sequenced

About this condition

Hereditary Paraganglioma-Pheochromocytoma

Hereditary paraganglioma-pheochromocytoma (PGL/PCC) syndromes are a group of autosomal dominant tumor predisposition disorders caused by germline pathogenic variants in genes encoding subunits or assembly factors of the succinate dehydrogenase (SDH) complex — a component of the mitochondrial electron transport chain (Complex II). The four clinically characterized syndromes are: PGL1 (SDHD), PGL2 (SDHAF2), PGL3 (SDHC), and PGL4 (SDHB), collectively accounting for approximately 10-15% of all paraganglioma and pheochromocytoma cases. When all hereditary causes are considered — including VHL, RET, NF1, TMEM127, MAX, and FH — up to 35-40% of apparently sporadic pheochromocytomas and paragangliomas have an underlying germline cause.

The clinical characteristics of PGL/PCC syndromes vary by causative gene in ways that directly inform management. SDHB pathogenic variants are associated with the highest rate of malignant paraganglioma — approximately 30-40% of SDHB-associated tumors are malignant, compared to approximately 5-10% for SDHD variants and rare malignancy in SDHC. SDHD variants are typically maternally imprinted — disease manifests almost exclusively in individuals who inherit the variant from their father (the maternal copy is silenced by imprinting), a unique inheritance feature whose failure to recognize leads to missed diagnoses in offspring of female SDHD carriers. SDHD carriers tend to have multifocal head and neck paragangliomas.

The broad differential diagnosis in hereditary PGL/PCC requires comprehensive multigene evaluation at first presentation. VHL syndrome (VHL gene), MEN2 (RET gene), and neurofibromatosis type 1 (NF1) each cause pheochromocytoma and require very different surveillance and management. The specific germline gene identified determines surveillance intensity, body sites requiring imaging, frequency of monitoring, family cascade testing approach, and surgical strategy for multifocal disease. Current guidelines from NCCN and the Endocrine Society recommend germline genetic testing in all patients presenting with paraganglioma, pheochromocytoma, or both, with comprehensive multigene panel analysis as the preferred approach.

SDHD inheritance is paternally imprinted — children of female SDHD carriers do not develop disease even when they inherit the variant, while children of male SDHD carriers face standard autosomal dominant risk. This unique feature must inform genetic counseling.

Gene locus
SDHB (1p36.13), SDHC (1q23.3), SDHD (11q23.1), SDHAF2 (11q12.2)

Sequential single-gene testing for PGL/PCC is clinically obsolete — up to 12 different genes can cause hereditary PGL/PCC, and a multigene result is required to rule out hereditary disease. Whole genome sequencing evaluates all of them simultaneously.

A negative SDHB result does not rule out hereditary PGL/PCC — SDHC, SDHD, VHL, RET, and others must also be evaluated

In patient populations presenting with paraganglioma, 35-40% have a germline cause. Single-gene SDHB testing — often ordered first because SDHB malignancy risk is highest — identifies only one of multiple possible hereditary causes. If SDHB is negative, SDHD (the second most common SDH gene), SDHC, SDHAF2, VHL, RET (MEN2), NF1, TMEM127, and MAX must each be evaluated to complete the hereditary workup. Sequential single-gene testing introduces months of delay and multiple sampling events. Whole genome sequencing evaluates all hereditary PGL/PCC genes simultaneously in a single test, providing a definitive hereditary vs. sporadic assessment at first presentation.

SDHB malignancy risk changes surveillance frequency and surgical aggressiveness

Management of hereditary PGL/PCC is gene-specific. SDHB carriers with resected primary tumors require more frequent post-operative surveillance imaging — typically annual whole-body PRRT/PET or MRI — because of the 30-40% malignant transformation rate. SDHD carriers are monitored for multifocal head and neck lesions and frequently undergo active surveillance for slow-growing primary head and neck paragangliomas rather than immediate surgical resection. The differences in surveillance intensity, imaging modality choice, and surgical decision-making between SDHB and SDHD carriers are significant — a distinction that requires a precise molecular diagnosis from a complete multigene evaluation.

Others in Hereditary Cancer

Browse all conditions →

One test. A lifetime of answers.

One kit, sent to your home. Your entire genome sequenced at the clinical standard used for diagnostic decisions. 200+ physician-ready reports delivered to your Genome Manager in 6–8 weeks — permanent and updated as science advances.

From $449

Ships within 48 hours · Results in 6–8 weeks

Get my Genome Test